AP2004003074A0 - Adjuvanted antigenic meningococcal compositions - Google Patents

Adjuvanted antigenic meningococcal compositions

Info

Publication number
AP2004003074A0
AP2004003074A0 APAP/P/2004/003074A AP2004003074A AP2004003074A0 AP 2004003074 A0 AP2004003074 A0 AP 2004003074A0 AP 2004003074 A AP2004003074 A AP 2004003074A AP 2004003074 A0 AP2004003074 A0 AP 2004003074A0
Authority
AP
ARIPO
Prior art keywords
compositions
adjuvanted
meningococcal compositions
adjuvanted antigenic
antigenic meningococcal
Prior art date
Application number
APAP/P/2004/003074A
Other languages
English (en)
Inventor
Mariagrazia Pizza
Marzia Monica Giuliani
Original Assignee
Chiron Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Spa filed Critical Chiron Spa
Publication of AP2004003074A0 publication Critical patent/AP2004003074A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
APAP/P/2004/003074A 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions AP2004003074A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
PCT/IB2002/005662 WO2003047619A2 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Publications (1)

Publication Number Publication Date
AP2004003074A0 true AP2004003074A0 (en) 2004-06-30

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003074A AP2004003074A0 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Country Status (11)

Country Link
US (2) US20060008476A1 (https=)
EP (1) EP1448230B1 (https=)
JP (2) JP4414226B2 (https=)
AP (1) AP2004003074A0 (https=)
AT (1) ATE485055T1 (https=)
AU (1) AU2002353417A1 (https=)
CA (1) CA2468935C (https=)
CY (1) CY1111114T1 (https=)
DE (1) DE60238075D1 (https=)
GB (1) GB0129007D0 (https=)
WO (1) WO2003047619A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
NZ521531A (en) * 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
AU2002346249B2 (en) * 2001-06-07 2007-03-15 The Regents Of The University Of Colorado Mutant Forms of Cholera Holotoxin as an Adjuvant
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012059593A1 (en) * 2010-11-05 2012-05-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3897706A4 (en) 2018-12-21 2022-11-23 Griffith University COMPOSITIONS, METHODS AND USES FOR INDURING AN IMMUNE RESPONSE
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021067628A2 (en) * 2019-10-01 2021-04-08 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2671261A1 (en) * 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
EP1047784B2 (en) * 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
PT1117435E (pt) * 1998-09-30 2008-02-21 Us Gov Univ Health Sciences Holotoxina da cólera mutante como adjuvante
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
US20100233205A1 (en) 2010-09-16
AU2002353417A1 (en) 2003-06-17
DE60238075D1 (de) 2010-12-02
CA2468935A1 (en) 2003-06-12
JP4414226B2 (ja) 2010-02-10
EP1448230B1 (en) 2010-10-20
ATE485055T1 (de) 2010-11-15
CA2468935C (en) 2013-02-05
WO2003047619A2 (en) 2003-06-12
CY1111114T1 (el) 2015-06-11
GB0129007D0 (en) 2002-01-23
EP1448230A2 (en) 2004-08-25
US20060008476A1 (en) 2006-01-12
WO2003047619A3 (en) 2003-10-23
JP2009155344A (ja) 2009-07-16
JP2005511662A (ja) 2005-04-28

Similar Documents

Publication Publication Date Title
AP2004003074A0 (en) Adjuvanted antigenic meningococcal compositions
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
DK2263688T4 (da) Kombinationsvacciner mod neisseria meningitidis
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
PT1235589E (pt) Composições compreendendo antigénios da neisseria meningitidis dos serogrupos b e c, e outro antigénio
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
WO2002009643A3 (en) Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
MA30065B1 (fr) Vaccin
AU2002252638A1 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
HU1000593D0 (en) Vaccine compositions
PT2289545T (pt) Vacina de omv suplementada contra meningococos
WO2002091998A3 (en) Novel meningitis conjugate vaccine
AU2168902A (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
EA200801368A1 (ru) Конъюгатные вакцины
NZ500159A (en) Detoxified mutants of bacterial adp-ribosylating toxins as parenteral adjuvants
WO2002028888A3 (en) Mimotope of neisseria meningitides lipooligosaccharide and vaccines containing the same
JP2007516219A5 (https=)
NZ515936A (en) Antigenic Neisserial peptides
EP2364725A3 (en) Immunization method against neisseria meningitidis serogroups a and c
AU2003255275A1 (en) Improved anthrax vaccines and delivery methods
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use